Total Clarity Wealth Management Inc. Trims Holdings in Repligen Co. (NASDAQ:RGEN)

Total Clarity Wealth Management Inc. cut its position in shares of Repligen Co. (NASDAQ:RGEN) by 4.9% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,940 shares of the biotechnology company’s stock after selling 150 shares during the quarter. Total Clarity Wealth Management Inc.’s holdings in Repligen were worth $371,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of RGEN. Evoke Wealth LLC acquired a new position in Repligen in the fourth quarter valued at $1,955,000. Norden Group LLC increased its stake in shares of Repligen by 1,711.6% during the 1st quarter. Norden Group LLC now owns 38,805 shares of the biotechnology company’s stock valued at $7,137,000 after acquiring an additional 36,663 shares during the last quarter. Artemis Investment Management LLP lifted its holdings in shares of Repligen by 33.8% during the 1st quarter. Artemis Investment Management LLP now owns 167,813 shares of the biotechnology company’s stock worth $30,852,000 after acquiring an additional 42,380 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in shares of Repligen by 30.2% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 28,883 shares of the biotechnology company’s stock worth $5,312,000 after acquiring an additional 6,705 shares during the last quarter. Finally, Congress Asset Management Co. MA grew its holdings in Repligen by 14.6% in the first quarter. Congress Asset Management Co. MA now owns 88,013 shares of the biotechnology company’s stock valued at $16,187,000 after purchasing an additional 11,213 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on RGEN shares. Guggenheim began coverage on shares of Repligen in a report on Tuesday, June 18th. They issued a “neutral” rating on the stock. Stephens reiterated an “overweight” rating and issued a $170.00 target price on shares of Repligen in a report on Tuesday, July 30th. Royal Bank of Canada restated an “outperform” rating and set a $190.00 price target on shares of Repligen in a research note on Wednesday, July 31st. JPMorgan Chase & Co. lifted their price objective on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Wednesday, July 31st. Finally, Deutsche Bank Aktiengesellschaft raised shares of Repligen from a “hold” rating to a “buy” rating and dropped their target price for the stock from $180.00 to $155.00 in a research report on Wednesday, June 26th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $188.38.

Insider Buying and Selling

In other Repligen news, VP Ralf Kuriyel sold 4,465 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $165.67, for a total value of $739,716.55. Following the completion of the transaction, the vice president now directly owns 19,261 shares of the company’s stock, valued at approximately $3,190,969.87. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other Repligen news, VP Ralf Kuriyel sold 4,465 shares of Repligen stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $165.67, for a total transaction of $739,716.55. Following the sale, the vice president now directly owns 19,261 shares in the company, valued at approximately $3,190,969.87. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Anthony Hunt sold 22,191 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the transaction, the director now owns 139,840 shares of the company’s stock, valued at $20,328,540.80. The disclosure for this sale can be found here. 1.20% of the stock is currently owned by insiders.

Repligen Price Performance

RGEN stock opened at $140.00 on Tuesday. The firm has a market cap of $7.82 billion, a P/E ratio of 560.00, a price-to-earnings-growth ratio of 4.20 and a beta of 0.94. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.56 and a current ratio of 6.65. Repligen Co. has a 1 year low of $110.45 and a 1 year high of $211.13. The stock has a 50-day simple moving average of $145.84 and a 200-day simple moving average of $156.46.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.33. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. The company had revenue of $154.07 million during the quarter, compared to the consensus estimate of $154.11 million. During the same quarter last year, the company earned $0.53 earnings per share. Repligen’s revenue for the quarter was down 3.2% on a year-over-year basis. On average, equities analysts predict that Repligen Co. will post 1.45 earnings per share for the current fiscal year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.